Chromatin proteins and modifications as drug targets

Kristian Helin () and Dashyant Dhanak ()
Additional contact information
Kristian Helin: Biotech Research and Innovation Centre, University of Copenhagen
Dashyant Dhanak: Janssen Research & Development

Nature, 2013, vol. 502, issue 7472, 480-488

Abstract: Abstract A plethora of groundbreaking studies have demonstrated the importance of chromatin-associated proteins and post-translational modifications of histones, proteins and DNA (so-called epigenetic modifications) for transcriptional control and normal development. Disruption of epigenetic control is a frequent event in disease, and the first epigenetic-based therapies for cancer treatment have been approved. A generation of new classes of potent and specific inhibitors for several chromatin-associated proteins have shown promise in preclinical trials. Although the biology of epigenetic regulation is complex, new inhibitors such as these will hopefully be of clinical use in the coming years.

Date: 2013
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature12751 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:502:y:2013:i:7472:d:10.1038_nature12751

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature12751

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().